NASDAQ:RTRX - Retrophin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.60 -0.63 (-2.60 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$24.23
Today's Range$23.54 - $24.24
52-Week Range$19.77 - $33.00
Volume182,107 shs
Average Volume362,051 shs
Market Capitalization$977.28 million
P/E Ratio-9.29
Dividend YieldN/A
Beta1.02
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$164.25 million
Book Value$7.72 per share

Profitability

Net Income$-102,680,000.00

Miscellaneous

Employees214
Market Cap$977.28 million
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) announced its earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.42. The biopharmaceutical company had revenue of $43.77 million for the quarter, compared to the consensus estimate of $43.54 million. Retrophin had a negative net margin of 62.51% and a negative return on equity of 33.53%. Retrophin's quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted $0.07 earnings per share. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Retrophin.

What price target have analysts set for RTRX?

5 equities research analysts have issued 1-year price targets for Retrophin's shares. Their predictions range from $43.00 to $57.00. On average, they expect Retrophin's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price. View Analyst Price Targets for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

Has Retrophin been receiving favorable news coverage?

News articles about RTRX stock have trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Retrophin earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the next few days.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Ms. Elizabeth E. Reed, Gen. Counsel & Corp. Sec. (Age 48)
  • Dr. William E. Rote, Sr. VP of R&D (Age 56)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director

Who are Retrophin's major shareholders?

Retrophin's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.10%), Macquarie Group Ltd. (5.49%), Bank of America Corp DE (2.97%), Dimensional Fund Advisors LP (2.80%), Dimensional Fund Advisors LP (2.80%) and Broadfin Capital LLC (2.46%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which major investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Jennison Associates LLC, Tavio Capital LLC, First Trust Advisors LP, Falcon Point Capital LLC, Prudential Financial Inc., PNC Financial Services Group Inc. and Oak Ridge Investments LLC. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.

Which major investors are buying Retrophin stock?

RTRX stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Macquarie Group Ltd., Two Sigma Investments LP, D. E. Shaw & Co. Inc., Handelsbanken Fonder AB, Perceptive Advisors LLC, Broadfin Capital LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $23.60.

How big of a company is Retrophin?

Retrophin has a market capitalization of $977.28 million and generates $164.25 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Retrophin employs 214 workers across the globe.

What is Retrophin's official website?

The official website for Retrophin is http://www.retrophin.com.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Featured Article: Institutional Investors

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel